Panitumumab

Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4].

Product Specifications

CAS Number

[339177-26-3]

Product Name Alternative

ABX-EGF

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/panitumumab.html

Purity

99.77

Solubility

H2O

Smiles

[Panitumumab]

Molecular Weight

(144.32 kDa)

References & Citations

[1]Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc) . 2006 Nov;42 (11) :711-9.|[2]Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13 (6) :843-51.|[3]Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6) : 1536–1546.|[4]Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29 (12) :5077-82.|[5]Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29 (12) :5077-82. PMID: 20044619.. . .